APA (7th ed.) Citation

Berclaz, L. M., Jurinovic, V., Burkhard‐Meier, A., Abdel‐Rahman, S., Albertsmeier, M., Klein, A., . . . Lindner, L. H. (2025). Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis. Cancer Medicine, 14(4), 1. https://doi.org/10.1002/cam4.70655

Chicago Style (17th ed.) Citation

Berclaz, Luc M., et al. "Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis." Cancer Medicine 14, no. 4 (2025): 1. https://doi.org/10.1002/cam4.70655.

MLA (9th ed.) Citation

Berclaz, Luc M., et al. "Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis." Cancer Medicine, vol. 14, no. 4, 2025, p. 1, https://doi.org/10.1002/cam4.70655.